Fig. 2

Comparison of outcomes in patients newly treated with pirfenidone or nintedanib. a Comparison of overall mortality in patients newly treated with pirfenidone or nintedanib;^a b Comparison of acute respiratory-related hospital admissions during the drug-exposure period in patients newly treated with pirfenidone or nintedanib;^b c Comparative incidence of discontinuation of pirfenidone or nintedanib treatment.^b CI confidence interval, m month, y year. ^aCumulative mortality was estimated using a cumulative incidence function. ^bCumulative incidence was estimated using a cumulative incidence function. The coloured areas represent the 95% CI